查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1485949

全球脂质体市场 - 全球产业分析、规模、占有率、成长、趋势、预测 (2031) - 依产品、依应用、依分销管道、依地区

Liposomes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 201 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球脂质体市场规模预计将从2024年的74亿美元大幅扩张至2031年的106.7亿美元，复合年增长率为5.2%。它是由药物输送系统的进步和慢性病的增加所推动的。

脂质体给药系统的创新正在彻底改变製药业。脂质体以其尺寸小、生物相容性和化学稳定性而闻名，这使得它们对于奈米医学至关重要。脂质体能够增强活性药物成分的功效，例如延长保质期和改进配方，这就是选择脂质体用于药物递送的原因。

脂质体製剂已被开发为皮肤病学和其他医学领域的局部治疗剂，凸显了基于脂质体的技术日益增长的重要性。随着技术的进步，脂质体奈米技术有望成为更可靠的製造平台，特别是在公共卫生和医疗诊断领域。

本报告调查了全球脂质体市场，并提供了市场概况，以及依产品、应用、分销管道、区域划分的趋势以及进入市场的公司的竞争趋势。

目录

第 1 章执行摘要

第二章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰与俄罗斯衝突的影响
  • 经济概况
  • 杵分析

第三章全球脂质体市场展望，2018-2031

  • 2018-2031 年全球脂质体市场前景（依产品、价值（十亿美元））
  • 2018-2031 年全球脂质体市场前景（依应用、价值（十亿美元））
  • 2018-2031 年全球脂质体市场展望，依通路划分，价值（十亿美元）
  • 2018-2031 年全球脂质体市场展望（依地区、价值（十亿美元））

第四章北美脂质体市场展望，2018-2031

第五章欧洲脂质体市场展望，2018-2031

第六章亚太地区脂质体市场展望，2018-2031

第 7 章拉丁美洲脂质体市场展望，2018-2031

第8章中东与非洲脂质体市场展望，2018-2031

第九章竞争态势

  • 依产品和应用划分的热图
  • 2023 年公司市占率分析
  • 竞争对手仪表板
  • 公司简介
    • Novartis AG (Liposoma BV)
    • Precision NanoSystems Inc
    • Janssen Pharmaceutical Companies
    • Encapsula Nano Sciences
    • Synpac-Kingdom Pharmaceutical Co., Ltd
    • Celsion GmbH
    • Gilead Sciences, Inc
    • Pacira BioSciences, Inc.
    • Luye Pharma Group
    • Sun Pharma Industries Ltd

第 10 章附录

简介目录

The global liposomes market is projected to experience significant expansion, with valuations anticipated to rise from $7.4 billion in 2024 to an impressive $10.67 billion by 2031. This represents a consistent CAGR of 5.2%, driven by advancements in drug delivery systems and the rising prevalence of chronic diseases.

Technological Breakthroughs in Liposomal Drug Delivery Systems

Innovations in liposomal drug delivery systems are revolutionizing the pharmaceutical industry. Known for their small size, biocompatibility, and chemical stability, liposomes have become integral in nanomedicine. Their ability to enhance the effectiveness of active pharmaceutical ingredients-such as prolonging shelf life and improving drug formulations-has made them a preferred choice for drug delivery.

The development of liposomal formulations for topical treatments in dermatology and other medical applications highlights the growing importance of liposome-based technologies. As technology advances, liposomal nanotechnology is expected to become a more dependable manufacturing platform, especially in public health and medical diagnostics.

Rising Demand for Liposomal Drugs

The demand for liposomal drugs is increasing due to the higher prevalence of chronic diseases, cancer, and lifestyle-related disorders such as diabetes and obesity. Liposomal drugs provide a promising solution for treating severe diseases because of their targeted delivery mechanisms and minimized side effects.

In emerging markets such as India, Mexico, and Brazil, the expanding patient population and greater awareness of health and wellness present substantial market opportunities. The increasing disposable income and economic growth in these regions further support the long-term viability of the liposomes market.

Enhancing Healthcare Infrastructure

The improvement of healthcare infrastructure and increased healthcare spending by governments in both developed and developing nations are key drivers of market growth. Better healthcare infrastructure enhances access to advanced therapeutics, thereby increasing the demand for liposomal drugs.

In countries like the United States, the high prevalence of chronic diseases, a strong healthcare infrastructure, and the presence of leading market players are contributing to market growth. For example, the American Cancer Society's 2022 report noted over 1.9 million new cancer cases and more than 609,360 cancer-related deaths, highlighting the need for advanced therapeutics.

Promising Market in Germany

Germany's extensive research and development activities in lipid pharmaceuticals, particularly for cardiovascular diseases (CVDs), are expected to further drive the liposomes market. With cardiovascular disorders being the leading cause of death in Germany-accounting for over 40% of all fatalities-the development of novel liposomal medications is crucial for reducing the prevalence and healthcare costs associated with CVDs.

Emerging Market in China

China is emerging as a key market for liposomes, driven by the increasing prevalence of chronic diseases, a growing elderly population, and market penetration by international players. The country's large patient pool and demand for new medications, such as liposomal drugs, present significant growth opportunities.

Key Distribution Channels

Pharmacies are the primary distribution channel for liposomal drugs, holding around 90.2% of the total market share in 2022. The high prevalence of chronic and skin diseases fuels the demand for liposomal drugs for therapeutic purposes. According to WHO estimates, non-communicable diseases (NCDs) cause 41 million deaths annually, with cardiovascular diseases and cancers being the leading causes.

Competitive Landscape

Leading players in the liposomes market are employing various strategies, including collaborations and the launch of new products. Notable developments include:

  • In January 2022, Pfizer Inc. and Acuitas Therapeutics signed a development and opportunity agreement, allowing Pfizer to develop vaccines using Acuitas' lipid nanoparticle (LNP) technology.
  • In October 2021, Evonik introduced a new version of LIPEX(R) liposome extruders. LIPEX(R) Flow offers a superior solution for drug designers and manufacturers, aiding the market introduction of liposomal pharmaceuticals.

The global liposomes market is set to witness considerable growth in the coming years, driven by technological advancements, increasing demand for advanced therapeutics, and strategic collaborations among key players.

Key Market Players Include

  • Novartis AG (Liposoma BV)
  • Precision NanoSystems Inc
  • Janssen Pharmaceutical Companies (Johnson & Johnson)
  • Encapsula Nano Sciences
  • Synpac-Kingdom Pharmaceutical Co., Ltd
  • Celsion GmbH
  • Gilead Sciences, Inc
  • Pacira BioSciences, Inc.
  • Luye Pharma Group
  • Sun Pharma Industries Ltd
  • Shanghai New Asia Pharmaceutical Co., Ltd.
  • ENERGY DELIVERY SOLUTIONs
  • Creative Biolabs
  • Nanovex Biotechnologies SL
  • Insys Therapeutics Inc
  • Fujifilm Holdings Corporation
  • Virpax Pharmaceuticals
  • Azaya Therapeutics
  • Avanti Polar Lipids, Inc.
  • Breath Therapeutics (Zambon company)
  • Getwell
  • Taiwan Liposome Company Ltd
  • Fresenius Health Care Group
  • Xellia Pharmaceuticals (Novo Holdings A/S)
  • Jazz Pharmaceuticals plc
  • Ipsen Biopharmaceuticals, Inc.
  • Baxter
  • GMPriority Pharma
  • S. G. Biopharm Pvt. Ltd

Global Liposomes market is Segmented as Below:

By Product:

  • Simple Liposomes
  • Formulated Liposomes
    • Doxorubicin Liposomes
    • Amphotericin B Liposomes
    • Paclitaxel Liposomes
    • Cytarabine Liposomes
    • Irinotecan Liposomes
    • Cisplatin Liposomes
    • Others
  • Vaccines

By Application:

  • Drug delivery
    • Cancer
    • Fungal Infection
    • Viral & Parasite Infection
    • Others
  • Gene Delivery/Transfection
  • Contrast agents for medical imaging
  • Model Cell Membranes

By Distribution Channel:

  • Retail Sales
    • Academic & Research Laboratories
    • Biopharmaceutical Companies
    • Clinical Research Organizations
    • Others
  • Distributional Sales
    • Hospital Pharmacies
    • Retail Pharmacies
    • Mail Order Pharmacies
    • Drug Stores

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Liposomes Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Liposomes Market Outlook, 2018 - 2031

  • 3.1. Global Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Simple Liposomes
      • 3.1.1.2. Formulated Liposomes
        • 3.1.1.2.1. Doxorubicin Liposomes
        • 3.1.1.2.2. Amphotericin B Liposomes
        • 3.1.1.2.3. Paclitaxel Liposomes
        • 3.1.1.2.4. Cytarabine Liposomes
        • 3.1.1.2.5. Irinotecan Liposomes
        • 3.1.1.2.6. Cisplatin Liposomes
        • 3.1.1.2.7. Others
      • 3.1.1.3. Vaccines
  • 3.2. Global Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Drug delivery
        • 3.2.1.1.1. Cancer
        • 3.2.1.1.2. Fungal Infection
        • 3.2.1.1.3. Viral & Parasite Infection
        • 3.2.1.1.4. Others
      • 3.2.1.2. Gene Delivery/Transfection
      • 3.2.1.3. Contrast agents for medical imaging
      • 3.2.1.4. Model Cell Membranes
  • 3.3. Global Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Retail Sales
        • 3.3.1.1.1. Academic & Research Laboratories
        • 3.3.1.1.2. Biopharmaceutical Companies
        • 3.3.1.1.3. Clinical Research Organizations
        • 3.3.1.1.4. Others
      • 3.3.1.2. Distributional Sales
        • 3.3.1.2.1. Hospital Pharmacies
        • 3.3.1.2.2. Retail Pharmacies
        • 3.3.1.2.3. Mail Order Pharmacies
        • 3.3.1.2.4. Drug Stores
  • 3.4. Global Liposomes Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Liposomes Market Outlook, 2018 - 2031

  • 4.1. North America Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Simple Liposomes
      • 4.1.1.2. Formulated Liposomes
        • 4.1.1.2.1. Doxorubicin Liposomes
        • 4.1.1.2.2. Amphotericin B Liposomes
        • 4.1.1.2.3. Paclitaxel Liposomes
        • 4.1.1.2.4. Cytarabine Liposomes
        • 4.1.1.2.5. Irinotecan Liposomes
        • 4.1.1.2.6. Cisplatin Liposomes
        • 4.1.1.2.7. Others
      • 4.1.1.3. Vaccines
  • 4.2. North America Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Drug delivery
        • 4.2.1.1.1. Cancer
        • 4.2.1.1.2. Fungal Infection
        • 4.2.1.1.3. Viral & Parasite Infection
        • 4.2.1.1.4. Others
      • 4.2.1.2. Gene Delivery/Transfection
      • 4.2.1.3. Contrast agents for medical imaging
      • 4.2.1.4. Model Cell Membranes
  • 4.3. North America Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Retail Sales
        • 4.3.1.1.1. Academic & Research Laboratories
        • 4.3.1.1.2. Biopharmaceutical Companies
        • 4.3.1.1.3. Clinical Research Organizations
        • 4.3.1.1.4. Others
      • 4.3.1.2. Distributional Sales
        • 4.3.1.2.1. Hospital Pharmacies
        • 4.3.1.2.2. Retail Pharmacies
        • 4.3.1.2.3. Mail Order Pharmacies
        • 4.3.1.2.4. Drug Stores
  • 4.4. North America Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Liposomes Market Outlook, 2018 - 2031

  • 5.1. Europe Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Simple Liposomes
      • 5.1.1.2. Formulated Liposomes
        • 5.1.1.2.1. Doxorubicin Liposomes
        • 5.1.1.2.2. Amphotericin B Liposomes
        • 5.1.1.2.3. Paclitaxel Liposomes
        • 5.1.1.2.4. Cytarabine Liposomes
        • 5.1.1.2.5. Irinotecan Liposomes
        • 5.1.1.2.6. Cisplatin Liposomes
        • 5.1.1.2.7. Others
      • 5.1.1.3. Vaccines
  • 5.2. Europe Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Drug delivery
        • 5.2.1.1.1. Cancer
        • 5.2.1.1.2. Fungal Infection
        • 5.2.1.1.3. Viral & Parasite Infection
        • 5.2.1.1.4. Others
      • 5.2.1.2. Gene Delivery/Transfection
      • 5.2.1.3. Contrast agents for medical imaging
      • 5.2.1.4. Model Cell Membranes
  • 5.3. Europe Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Retail Sales
        • 5.3.1.1.1. Academic & Research Laboratories
        • 5.3.1.1.2. Biopharmaceutical Companies
        • 5.3.1.1.3. Clinical Research Organizations
        • 5.3.1.1.4. Others
      • 5.3.1.2. Distributional Sales
        • 5.3.1.2.1. Hospital Pharmacies
        • 5.3.1.2.2. Retail Pharmacies
        • 5.3.1.2.3. Mail Order Pharmacies
        • 5.3.1.2.4. Drug Stores
  • 5.4. Europe Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Liposomes Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Simple Liposomes
      • 6.1.1.2. Formulated Liposomes
        • 6.1.1.2.1. Doxorubicin Liposomes
        • 6.1.1.2.2. Amphotericin B Liposomes
        • 6.1.1.2.3. Paclitaxel Liposomes
        • 6.1.1.2.4. Cytarabine Liposomes
        • 6.1.1.2.5. Irinotecan Liposomes
        • 6.1.1.2.6. Cisplatin Liposomes
        • 6.1.1.2.7. Others
      • 6.1.1.3. Vaccines
  • 6.2. Asia Pacific Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Drug delivery
        • 6.2.1.1.1. Cancer
        • 6.2.1.1.2. Fungal Infection
        • 6.2.1.1.3. Viral & Parasite Infection
        • 6.2.1.1.4. Others
      • 6.2.1.2. Gene Delivery/Transfection
      • 6.2.1.3. Contrast agents for medical imaging
      • 6.2.1.4. Model Cell Membranes
  • 6.3. Asia Pacific Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Retail Sales
        • 6.3.1.1.1. Academic & Research Laboratories
        • 6.3.1.1.2. Biopharmaceutical Companies
        • 6.3.1.1.3. Clinical Research Organizations
        • 6.3.1.1.4. Others
      • 6.3.1.2. Distributional Sales
        • 6.3.1.2.1. Hospital Pharmacies
        • 6.3.1.2.2. Retail Pharmacies
        • 6.3.1.2.3. Mail Order Pharmacies
        • 6.3.1.2.4. Drug Stores
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Liposomes Market Outlook, 2018 - 2031

  • 7.1. Latin America Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Simple Liposomes
      • 7.1.1.2. Formulated Liposomes
        • 7.1.1.2.1. Doxorubicin Liposomes
        • 7.1.1.2.2. Amphotericin B Liposomes
        • 7.1.1.2.3. Paclitaxel Liposomes
        • 7.1.1.2.4. Cytarabine Liposomes
        • 7.1.1.2.5. Irinotecan Liposomes
        • 7.1.1.2.6. Cisplatin Liposomes
        • 7.1.1.2.7. Others
      • 7.1.1.3. Vaccines
  • 7.2. Latin America Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Drug delivery
        • 7.2.1.1.1. Cancer
        • 7.2.1.1.2. Fungal Infection
        • 7.2.1.1.3. Viral & Parasite Infection
        • 7.2.1.1.4. Others
      • 7.2.1.2. Gene Delivery/Transfection
      • 7.2.1.3. Contrast agents for medical imaging
      • 7.2.1.4. Model Cell Membranes
  • 7.3. Latin America Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Retail Sales
        • 7.3.1.1.1. Academic & Research Laboratories
        • 7.3.1.1.2. Biopharmaceutical Companies
        • 7.3.1.1.3. Clinical Research Organizations
        • 7.3.1.1.4. Others
      • 7.3.1.2. Distributional Sales
        • 7.3.1.2.1. Hospital Pharmacies
        • 7.3.1.2.2. Retail Pharmacies
        • 7.3.1.2.3. Mail Order Pharmacies
        • 7.3.1.2.4. Drug Stores
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Liposomes Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Liposomes Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Simple Liposomes
      • 8.1.1.2. Formulated Liposomes
        • 8.1.1.2.1. Doxorubicin Liposomes
        • 8.1.1.2.2. Amphotericin B Liposomes
        • 8.1.1.2.3. Paclitaxel Liposomes
        • 8.1.1.2.4. Cytarabine Liposomes
        • 8.1.1.2.5. Irinotecan Liposomes
        • 8.1.1.2.6. Cisplatin Liposomes
        • 8.1.1.2.7. Others
      • 8.1.1.3. Vaccines
  • 8.2. Middle East & Africa Liposomes Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Drug delivery
        • 8.2.1.1.1. Cancer
        • 8.2.1.1.2. Fungal Infection
        • 8.2.1.1.3. Viral & Parasite Infection
        • 8.2.1.1.4. Others
      • 8.2.1.2. Gene Delivery/Transfection
      • 8.2.1.3. Contrast agents for medical imaging
      • 8.2.1.4. Model Cell Membranes
  • 8.3. Middle East & Africa Liposomes Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Retail Sales
        • 8.3.1.1.1. Academic & Research Laboratories
        • 8.3.1.1.2. Biopharmaceutical Companies
        • 8.3.1.1.3. Clinical Research Organizations
        • 8.3.1.1.4. Others
      • 8.3.1.2. Distributional Sales
        • 8.3.1.2.1. Hospital Pharmacies
        • 8.3.1.2.2. Retail Pharmacies
        • 8.3.1.2.3. Mail Order Pharmacies
        • 8.3.1.2.4. Drug Stores
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Liposomes Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Liposomes Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Liposomes Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Liposomes Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Product vs by Application Heat map
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novartis AG (Liposoma BV)
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Precision NanoSystems Inc
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Janssen Pharmaceutical Companies (Johnson & Johnson
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Encapsula Nano Sciences
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Synpac-Kingdom Pharmaceutical Co., Ltd
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Celsion GmbH
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Gilead Sciences, Inc
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Pacira BioSciences, Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Luye Pharma Group
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Sun Pharma Industries Ltd
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1.Research Methodology
  • 10.2.Report Assumptions
  • 10.3.Acronyms and Abbreviations